MALTA-BASED GENERICS DEVELOPER AND MANUFACTURER PHARMACARE Premium believes it is leading the way on developing a generic pazopanib rival to Novartis’ Votrient cancer treatment for the European market. Malta-

Pharmacare Premium Claims Pole Position On Pazopanib – GB